Navigation Links
The Leading Edge Of Medical Innovation: New Prenatal Genetic Tests Use Mom's Blood To Learn About Her Baby

NEW YORK, Dec. 13, 2012 /PRNewswire-USNewswire/ -- New prenatal tests can give some parents piece of mind – sooner and with greater accuracy and less risk of miscarriage than current tests – that the baby they're expecting doesn't have a disorder.

The new tests, which use fetal DNA suspended in the mother's blood, can test for chromosomal disorders such as Down syndrome (trisomy 21) and trisomy 18, and Rh blood incompatibility. They also can determine fetal gender, which allows health care providers to screen for disorders carried on the X chromosome, such as hemophilia.

These medical advances are raising questions that expecting parents may feel ill-equipped to answer. They also raise new concerns about the ability of the medical field to counsel new parents and explain what the tests can reasonably predict and what they can't.

Two experts will address these issues at a luncheon for reporters sponsored by the March of Dimes. Diana W. Bianchi, MD, executive director, Mother Infant Research Institute at Tufts Medical Center and a professor of pediatrics and obstetrics and gynecology at Tufts University School of Medicine, will explain what the cell-free DNA tests are, how they differ from existing prenatal screens and tests, as well as their effectiveness.  Lee P. Shulman, MD, a professor of obstetrics and gynecology and director of the Northwestern Ovarian Cancer Early Detection and Prevention Program at the Feinberg School of Medicine of Northwestern University, will focus on consumer education about cell-free fetal DNA tests and explore questions parents should ask before and after such testing.

During pregnancy, fetal cells and cell-free fetal genetic material circulate in the mother's bloodstream.  This DNA can be used to screen for certain genetic disorders without having to perform invasive procedures such as amniocentesis or CVS (chorionic villus sampling).

At present four widely used procedures assist health care providers in prenatal diagnosis. They are:

  • Amniocentesis: a procedure that collects some of the amniotic fluid that surrounds the fetus for analysis. This is a diagnostic test.
  • Chorionic villus sampling (CVS): a procedure that obtains tissue from around the placenta. This is a diagnostic test.
  • Maternal blood tests: screening tests that use mother's blood to help identify problems with the fetal brain, spinal cord, intestines or chromosomes. These tests include alpha-fetoprotein (AFP), hCG and other hormones. As with all forms of screening, abnormal results require follow-up testing to make a diagnosis.
  • Ultrasound: a scan using sound waves to visualize the fetus.
    Cell-free DNA methods of screening are a new option.

"Prenatal diagnosis gives parents important information about the health of their baby and the status of their pregnancy. More often than not, prenatal screening reassures parents that their baby is healthy and that these disorders are not present," says Joe Leigh Simpson, MD, March of Dimes senior vice president for Research and Global Programs.  "For a high-risk infant, prenatal diagnosis gives parents and health care providers options that may include planning for a health problem or arranging for delivery in a medically appropriate setting. The first step toward treating these problems is diagnosing them, and cell-free DNA methods, without the need for invasive measures, are welcomed."

Dr. Bianchi says, "This cell-free DNA blood test also has the potential to push beyond the boundaries of what is currently being screened for."

"The introduction of new prenatal screening tests that evaluate cell-free nucleic acids in maternal blood represents a profound improvement in our ability to identify women at increased risk for carrying fetuses with the most common chromosome abnormalities," Dr. Shulman says. "Still, this technology represents a limited screening protocol and should not serve as a substitute for diagnostic tests such as chorionic villus sampling and amniocentesis, which provide the most accurate and comprehensive assessment by the direct analysis of fetal tissue."

The American College of Obstetricians and Gynecologists and the American College of Medical Genetics recommend that information on prenatal genetic screening and diagnosis should be made available to all pregnant women and those considering pregnancy.

The March of Dimes is the leading nonprofit organization for pregnancy and baby health.  With chapters nationwide and its premier event, March for Babies®, the March of Dimes works to improve the health of babies by preventing birth defects, premature birth and infant mortality. For the latest resources and information, visit or

SOURCE March of Dimes
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Crisalix Awarded as a Leading Life Science Company that is Revolutionizing the Medical Industry
2. Speech and Language Therapy Jobs and Biomedical Science Jobs - Medicspro Leading the way for Medical Recruitment Agencies in the UK
3. Japan Bioinformatics Announces Study on Leading Mapping Tools for DNA Mutation Discovery
4. A leading Massachusetts-based IT and Life Sciences staffing and consulting firm has opened two new offices in the Ohio Valley
5. Maker of leading in-home HIV test encourages testing
6. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
7. Leading India-USA based CRO Announces Data Management/EDC, Medical Writing Milestone
8. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
9. Dyadic Demonstrates Industry-leading Biofuels Enzyme Performance
10. Tanke BioSciences To Host Leading Symposium On Food Safety, June 24-25
11. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
Post Your Comments:
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
(Date:11/25/2015)... Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... business and prospects remain fundamentally strong and highlights ... doxorubicin) recently received DSMB recommendation to continue the ... review of the final interim efficacy and safety ... Endpoint in men with heavily pretreated castration- and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... in New York on Wednesday, December 2 ... Torley , president and CEO, will provide a corporate overview. ... York at 1:00 p.m. ET/10:00 a.m. PT . ... relations, will provide a corporate overview. --> th ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that it has been selected ... of only three finalists for a 2015 Tekne ... category. The Tekne Awards honor Minnesota ... and leadership. iMedNet™ eClinical  technology ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):